Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)
Clinical trial NCT04428151 · COMPLETED
Trial details
- NCT number
- NCT04428151
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-08-06
- Primary completion
- 2024-05-31
- Enrollment
- 408
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.